Pfizer’s Key Questions For CMO Innovation
This article discusses Big Pharma and CMO innovation challenges, and while it is not focused on cold chain, they do apply as well:
Among the edifying panels at this summer’s Outsourced Pharma San Diego, the one featuring Pfizer’s Bernie Huyghe – Technology in the supply chain – might have gained a conference apogee.
Except that, technically speaking, it wasn’t a panel. Instead, we took the conference differentiator – broad audience participation – to it’s extended conclusion: we did away with the panel altogether, and asked Huyghe (pronounced “highga”) to go it alone.
But it’s also not accurate to say Huyghe went solo; he was part of a dialogue with a room full of pharmaceutical and biotech, contract manufacturing organization (CMO), and other drug development and manufacturing professionals.
The objective was to gain insight into an overriding question:
How do we inject more innovation and technology into Pharma’s external drug development and manufacturing supply chain?
There is an example that is discussed which does touch on temperature related aspects of the supply chain:
If Big Pharma needs something that for whatever reason can’t be done internally, sure, we’ll pay for the efforts. An example is work we’re doing in cell therapy. Our drug product is a cryo-preserved vial. How do we label something stored in liquid nitrogen? Not only that, but we have to label it differently for global markets. Turns out we needed a new supply chain. We reached out to vendors and suppliers to help us settle these kinds of issues.
Source: Outsourced Pharma